GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » EV-to-Revenue

Frontage Holdings (HKSE:01521) EV-to-Revenue : 1.63 (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Frontage Holdings's enterprise value is HK$3,314 Mil. Frontage Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,032 Mil. Therefore, Frontage Holdings's EV-to-Revenue for today is 1.63.

The historical rank and industry rank for Frontage Holdings's EV-to-Revenue or its related term are showing as below:

HKSE:01521' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.66   Med: 6.62   Max: 16.47
Current: 1.63

During the past 8 years, the highest EV-to-Revenue of Frontage Holdings was 16.47. The lowest was 1.66. And the median was 6.62.

HKSE:01521's EV-to-Revenue is ranked better than
81.33% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs HKSE:01521: 1.63

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Frontage Holdings's stock price is HK$1.28. Frontage Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.98. Therefore, Frontage Holdings's PS Ratio for today is 1.30.


Frontage Holdings EV-to-Revenue Historical Data

The historical data trend for Frontage Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings EV-to-Revenue Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 9.47 7.59 5.16 3.18 2.70

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 - 3.18 - 2.70

Competitive Comparison of Frontage Holdings's EV-to-Revenue

For the Biotechnology subindustry, Frontage Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frontage Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's EV-to-Revenue falls into.



Frontage Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Frontage Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3314.407/2032.394
=1.63

Frontage Holdings's current Enterprise Value is HK$3,314 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,032 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frontage Holdings  (HKSE:01521) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Frontage Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.28/0.982
=1.30

Frontage Holdings's share price for today is HK$1.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.98.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frontage Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines